Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The company announced a restructuring plan to outsource manufacturing, potentially impacting revenue and profitability. This plan is expected to be completed by Q3 fiscal 2026.
- The asset purchase agreement with Spectrum Vascular resulted in a cash sale of $34.5 million and a pre-tax income of $6.7 million.
- International distributors accounted for 77% of revenues in fiscal year 2024, up from 72% in 2023.
- Geopolitical developments, including the Israel/Hamas war, may disrupt operations and impact financial results.
- The company recorded a goodwill impairment charge of $3.4 million due to restructuring activities in fiscal year 2024.
- The rapid increase in inflation during fiscal year 2024 led to higher market interest rates affecting floating-rate debt.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1275187&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.